Release Date: February 04, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: What is the status of the danuglipron dose optimization data, and is there a possibility of dropping this version of the compound? A: Chris Boshoff, Chief Scientific Officer and President, Research & Development, stated that the data from the ongoing dose optimization and formulation study is expected in the first quarter. The future of danuglipron will be determined based on this data.
Q: Can you provide insights into Pfizer's COVID franchise revenue stabilization and future investments? A: Aamir Malik, Executive Vice President, Chief US Commercial Officer, explained that Paxlovid utilization tracks directly with disease outbreaks, and the commercial model is effective. For Comirnaty, vaccination rates were stable, and Pfizer improved its market share. The company has multiyear contracts internationally, making the revenue stream stable and predictable.
Q: What is Pfizer's approach to capital allocation and business development in 2025? A: David Denton, Executive Vice President, Chief Financial Officer, mentioned that Pfizer has the capacity for business development transactions in the $10 billion to $15 billion range in 2025. Andrew Baum, Chief Strategy and Innovation Officer, added that any expansion into new therapeutic areas would focus on breakthrough science and unmet medical needs.
Q: How is Pfizer's RSV market strategy evolving, and what are the growth catalysts? A: Aamir Malik noted that while the RSV market may not grow without policy changes, there are midterm growth catalysts such as policy updates, age expansion, and revaccination recommendations. Alexandre De Germay, Executive Vice President, Chief International Commercial Officer, highlighted strong execution in international markets, with significant vaccination rates in the UK and France.
Q: What is the strategy for Pfizer's breast cancer portfolio, particularly with CDK4 and vepdeg? A: Chris Boshoff explained that Pfizer's CDK4 inhibitor is expected to replace existing CDK4/6 inhibitors in early-line breast cancer. The company is also planning a study combining vepdeg with CDK4 in first-line ER-positive breast cancer, aiming to establish a strong position in the evolving landscape.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.